Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
Type:
Application
Filed:
June 2, 2008
Publication date:
February 26, 2009
Applicant:
Apotech Research and Development Ltd.
Inventors:
Jurg Tschopp, Pascal Schneider, Nils Holler
Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. The oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.
Type:
Grant
Filed:
June 28, 2002
Date of Patent:
June 10, 2008
Assignee:
Apotech Research and Development Ltd.
Inventors:
Jürg Tschopp, Pascal Schneider, Nils Holler
Abstract: The use of inhibitors of cysteine aspartate proteins (caspases) for treating diseases or disorders caused by a hyperproliferation of peripheral blood lymphocytes is disclosed. The use of caspase inhibitors for suppressing the immune system is also disclosed.
Type:
Application
Filed:
October 9, 2001
Publication date:
July 4, 2002
Applicant:
APOTECH RESEARCH AND DEVELOPMENT LTD.
Inventors:
Ralph C. Budd, Jurg Tschopp, Takao Kataoka